Heparin Assays and Bleeding Complications in Treatment of Deep Venous Thrombosis with Particular Reference to Retroperitoneal Bleeding

Summary

Bleeding complications occurred in 30 (11%) out of 280 patients who received continuous heparin infusion for deep venous thrombosis (DVT). 22 (8%) had minor while 8 patients (3%) had major bleeding complications (1 intrathoracic [fatal], 2 gastrointestinal and 5 retroperitoneal). Heparin activity, in daily drawn blood samples, was determined by four assays (chromogenic substrate [CS] assay, activated partial thromboplastin time [APTT], thrombin time with citrated plasma [CiTT] and thrombin time with recalcified plasma [CaTT]). The differences in median heparin activity between patients with minor bleeding and patients with no bleeding did not reach significance for any of the tests. In patients with major bleeding, the differences were significant with the CS (p = .011) and the CaTT (p = .030) assays. Patients with retroperitoneal bleeding had significantly increased median activity judged by all four assays: CS (p = .002), CaTT (p = .003), APTT (p = .010), CiTT (p = .029). The difference was most pronounced after four days of heparin treatment, but there was a considerable overlap with patients without bleeding.

Keywords

Deep venous thrombosis - Heparin treatment - Heparin assays - Bleeding complications - Retroperitoneal bleeding

• References

• 1 Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy, controlled prospective trial. N Engl J Med 1975; 292: 1046-1050
• 2 Glazier RL, Crowell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 1976; 236: 1365-1367
• 3 Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980; 17: 259-291
• 4 Norman CS, Provan JL. Control and complications of intermittent heparin therapy. Surg Gynecol Obstet 1977; 145: 338-342
• 5 Pitney WR, Pettit JE, Armstrong L. Control of heparin therapy. Br Med J 1970; 4: 139-141
• 6 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327
• 7 Mant MJ, O’Brien BD, Thong KL, Hammond GW, Birtwhistle RV, Grace MG. Haemorrhagic complications of heparin therapy. Lancet 1977; 1: 1133-1135
• 8 Holm HA, Abildgaard U. et al The antithrombotic effect of heparin in deep venous thrombosis: Relation to four heparin assays. Acta Med Scand 1984; 216: 287-293
• 9 Holm HA, Finnanger B. et al Heparin treatment of deep venous thrombosis in 280 patients: Symptoms related to dosage. Acta Med Scand 1984; 215: 47-53
• 10 Blombäck M, Blombäck B, Olsson P, William-Olsson G, Senning Å. Determination of heparin level of the blood. Acta Chir Scand 1959; 245 (suppl) 259-264
• 11 Burstein M, Guinand A. Sur le temps de thrombine du plasma hépariné. Action des substances fibrinoplastiques Rev Hémat 1955; 10: 567-570
• 12 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
• 13 Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980; 244: 1209-1212
• 14 Jick H, Slone D, Borda IT, Shapiro S. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 1968; 279-286
• 15 Vieweg WV, Piscatelli RL, Houser JJ, Proulx RA. Complications of intravenous administration of heparin in elderly women. JAMA 1970; 213: 1303-1306
• 16 Willbanks OL, Fuller CH. Femoral neuropathy due to retroperitoneal bleeding. Arch Intern Med 1973; 132: 83-86
• 17 Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. J Biol Chem 1983; 258: 3803-3808
• 18 Bounameaux H, Marbet GA, Lämmle B, Eichlisberger R, Duckert F. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration and analysis of the behavior of antithrombin III. Am J Clin Pathol 1980; 74: 68-73